Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 6.70
- Piotroski Score 1.00
- Grade Overweight
- Symbol (SRRK)
- Company Scholar Rock Holding Corporation
- Price $37.80
- Changes Percentage (26.29%)
- Change $7.88
- Day Low $36.95
- Day High $43.38
- Year High $43.38
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/11/2025
- Fiscal Year End N/A
- Average Stock Price Target $40.50
- High Stock Price Target $42.00
- Low Stock Price Target $39.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.09
- Trailing P/E Ratio -4.55
- Forward P/E Ratio -4.55
- P/E Growth -4.55
- Net Income $-165,789,000
Income Statement
Quarterly
Annual
Latest News of SRRK
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Scholar Rock Holding Corp (SRRK) Q3 2024 Earnings Call Highlights: Strategic Advances and ...
The company plans to base dosing for the OPAL study on PK/PD data from previous trials, likely using 10 mg/kg. In obesity, they aim to preserve lean mass with SRK-439, complementing existing therapies...
By Yahoo! Finance | 1 week ago -
Scholar Rock Holding Corporation (SRRK) Stock Price, News, Quote & History - Yahoo Finance
Scholar Rock reports positive results from Phase 3 trial for apitegromab in treating spinal muscular atrophy and other disorders. Study shows promising efficacy and safety in patients....
By Yahoo! Finance | 1 month ago -
Scholar Rock Holding Corporation (NASDAQ:SRRK) Ranks High On The List Of Worst Falling Stocks To Buy Now
The article discusses Scholar Rock Holding Corporation's ranking among the worst falling stocks to buy now. It emphasizes the importance of considering fundamentals, market sentiment, news, and other ...
By Yahoo! Finance | 1 month ago
